BenevolentAI SPAC Presentation Deck
Cash runway beyond 2025 providing sufficient capital
for next stage of growth
Pro Forma cash of ~€445m provides
runway beyond 2025²
Cash Runway
BenevolentAl Cash¹
Odyssey cash held in trust²
PIPE
Transaction fees³
Total Pro Forma Cash
€m
€ 56
€ 300
€ 135
(€46)
€ 445
Source: Company information
Notes: (1) £47.5m, as of 30 Nov 2021, unaudited (2) Assumes no share redemptions from
ODYSY shareholders; (3) Expenses for both SPAC and target including deferred underwriting
fees, PIPE fee, financing fees, and advisory, legal, accounting and other fees.
Benevolent
2
4
Use of Proceeds
Completion of Phase I/II trial for PanTrk (Atopic
Dermatitis) and subsequent out-license
Completion of Phase I trial for PDE10 in Ulcerative Colitis
and commencement of Phase II trial in 2024
Up to 5 further Phase I trials and readouts by 2025
A technology platform continually innovating to
accelerate our global leadership in Al-enabled Drug
Discovery
A platform capable of delivering 5+ INDs per year from
2024 onwards
Benevolent 35View entire presentation